

In the Claims:

Please cancel claims 1-8 without prejudice or disclaimer and add the following new claims.

SUB B 3 9. (New) A method for inhibiting synovial cell growth, comprising administering to a patient in need thereof a pharmaceutical composition comprising a monoclonal antibody PM-1 and a physiologically acceptable carrier.

A₂ 10. (New) The method according to claim 9, wherein the antibody is a humanized antibody PM-1.

SUB B 4 11. (New) The method according to claim 9, wherein the patient is a human.

SUB B 5 12. (New) The method according to claim 11, wherein the antibody is administered in four divided doses from about 1 to 1000 mg.

SUB B 6 13. (New) The method of treating chronic rheumatoid arthritis, comprising administering to a patient in need thereof a pharmaceutical composition comprising a monoclonal antibody PM-1 and a physiologically acceptable carrier.

14. (New) The method according to claim 13, wherein the antibody suppresses abnormal growth of synovial cells.

SUB B 7 15. (New) The method according to claim 13, wherein the antibody is a humanized antibody PM-1.

SUB B 8 16. (New) The method according to claim 13, wherein the patient is a human.